Synthesis and Biological Evaluation of New Quinoxaline Derivatives as Antioxidant and Anti-Inflammatory Agents

Chemical Biology and Drug Design

Volumn 77, Issue 4, 2011, Pages 255-267

  Burguete, Asunción ^a,b   Pontiki, Eleni ^a   Hadjipavlou Litina, Dimitra ^a   Ancizu, Saioa ^b   Villar, Raquel ^b   Solano, Beatriz ^b   Moreno, Elsa ^b   Torres, Enrique ^b   Pérez, Silvia ^b   Aldana, Ignacio ^b   Monge, Antonio ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Anti inflammatory; Antioxidant; Quinoxaline; Quinoxaline 1,4 di N oxide

Indexed keywords

1 (3 METHYL QUINOXALIN 2 YL) 3 (3,4,5 TRIMETHOXYPHENYL)PROPENONE DERIVATIVE; 1 (SUBSTITUTED PHENYL) 2 (TRIPHENYLPHOSPHONYLIDENE)ETHANONE DERIVATIVE; 1,4 DIOXY QUINOXALINE 2 CARBALDEHYDE DERIVATIVE; 2 METHOXY 4 [5 (3 METHYL 1,4 DIOXYQUINOXALIN 2 YL) 3,4 DIHYDRO 2H PYRAZOL 3 YL] PHENOL DERIVATIVE; 2 METHYL 3 [5 (3,4,5 TRIMETHOXYPHENYL) 4,5 DIHYDRO 1H PYRAZOL 3 YL] QUINOXALINE DERIVATIVE; 3 (3 METHYL 1,4 DIOXYQUINOXALIN 2 YL) 1 (3,4,5 TRIMETHOXYPHENYL)PROPENONE DERIVATIVE; 4 (3 METHYL QUINOXALIN 2 YL) 6 (3,4,5 TRIMETHOXYPHENYL)PYRIMIDIN 2 YLAMINE DERIVATIVE; 4 [3 (3 METHYL QUINOXALIN 2 YL) 5 (3,4,5 TRIMETHOXYPHENYL) 4,5 DIHYDROPYRAZOL 1 YL] BENZENESULFONAMIDE DERIVATIVE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CARRAGEENAN; INDOMETACIN; LIPOXYGENASE INHIBITOR; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; EDEMA; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROWAVE RADIATION; NONHUMAN; PRIORITY JOURNAL; RAT; SOYBEAN;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; LIPOXYGENASE; MALE; MOLECULAR STRUCTURE; QUINOXALINES; RATS;

GLYCINE MAX;

EID: 79952591313     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01076.x     Document Type: Article

References (36)

1. Claesson H.E., Dahlen S.E. (1999) Asthma and leukotrienes: antileukotrienes as novel anti-asthmatic drugs. J Intern Med;245:205-227.
2. Dwyer J.H., Allayee H., Dwyer K.M., Fan J., Wu H., Mar R., Lusis A.J., Mehrabian M. (2004) Arachidonate 5-Lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med;350:29-37.
3. Hennig R., Ding X., Tong W., Schneider M.B., Standop J., Friess H., Büchler M.W., Pour P.M., Adrian T.E. (2002) 5-lipoxygenase and leukotriene B4 receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol;161:421-428.
4. Yoshimura R., Matsuyama M., Tsuchida K., Kawahito Y., Sano H., Nakatani T. (2003) Expression of lipoxygenase in human bladder carcinoma and growth inhibition by its inhibitors. J Urol;170:1994-1999.
5. Jiang W.G., Douglas-Jones A., Mansel R.E. (2003) Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. Prostaglandins Leukot Essent Fatty Acids;69:275-281.
6. Franco R., Schoneveld O., Georgakilas A.G., Panayiotidis M.I. (2008) Oxidative stress, DNA methylation and carcinogenesis. Cancer Lett;266:6-11.
7. Dhalla N.S., Temsah R.M., Netticadan T. (2000) Role of oxidative stress in cardiovascular diseases. J Hypertens;18:655-673.
8. Chen L., Liu L., Yin J., Luo Y., Huang S. (2009) Hydrogen peroxide-induced neuronal apoptosis is associated with inhibition of protein phosphatase 2A and 5, leading to activation of MAPK pathway. Int J Biochem Cell Biol;41:1284-1295.
9. Halliwell B., Hoult J.R., Blake D.R. (1988) Oxidants, inflammation, and anti-inflammatory drugs. FASEB J;2:2867-2873.
10. Weiss S.J. (1989) Tissue destruction by neutrophils. N Engl J Med;320:365-376.
11. Udassin R., Ariel I., Haskel Y., Kitrossky N., Chevion M. (1991) Salicylate as an in vivo free-radical trap: studies on ischemic insult to the rat intestine. Free Radic Biol Med;10:1-6.
12. Tsujimoto Y., Saitoh K., Kashima M., Shiozawa A., Kozuka M., Hashizume H., Kimura K., Yamazaki M., Fujii A. (1998) Effect of nonsteroidal anti-inflammatory drugs on lipid peroxidation by hydroxyl radical. Gen Pharmacol;31:405-408.
13. Maharaj H., Maharaj D.S., Daya S. (2006) Acetylsalicylic acid and acetaminophen protect against oxidative neurotoxicity. Metab Brain Dis;21:189-199.
14. Facino R.M., Carini M., Aldini G., Saibene L., Morelli R. (1995) Differential inhibition of superoxide, hydroxyl and peroxyl radicals by Nimesulide and its main metabolite 4-hydroxynimesulide. Arzneim Forsch Drug Res;45:1102-1109.
15. Vicente E., Villar R., Burguete A., Solano B., Perez-Silanes S., Aldana I., Maddry J.A., Lenaerts A.J., Franzblau S.G., Cho S., Monge A., Goldman R.C. (2008) Efficacy of quinoxaline-2-carboxylate 1, 4-di-N-oxide derivatives in experimental tuberculosis. Antimicrob Agents Chemother;52:3321-3326.
16. Zarranz B., Jaso A., Aldana I., Monge A. (2004) Synthesis and anticancer activity evaluation of new 2-alkylcarbonyl and 2-benzoyl-3-trifluoromethyl-quinoxaline 1, 4-di-N-oxide derivatives. Bioorg Med Chem;12:3711-3721.
17. Burguete A., Estevez Y., Castillo D., Gonzalez G., Villar R., Solano B., Vicente E., Pérez S., Aldana I., Monge A., Sauvain M., Deharo E. (2008) Anti-leishmanial and structure-activity relationship of ring substituted 3-phenyl-1-(1, 4-di-N-oxide quinoxalin-2-yl)-2-propen-1-one derivatives. Mem Inst Oswaldo Cruz;103:778-780.
18. Burguete A., Pontiki E., Hadjipavlou-Litina D., Villar R., Vicente E., Solano B., Ancizu S., Pérez-Silanes S., Aldana I., Monge A. (2007) Synthesis and anti-inflammatory/antioxidant activities of some new ring substituted 3-phenyl-1-(1, 4-di-N-oxide quinoxalin-2-yl)-2-propen-1-one derivatives and of their 4, 5-dihydro-(1H)-pyrazole analogues. Bioorg Med Chem Lett;17:6439-6443.
19. Monge A., Palop J.A., De Cerain A.L., Senador V., Martinez Crespo F.J., Sainz Y., Narro S., Garcia E., Demiguel C., Gonzalez M., Hamilton E., Barker A.J., Clarke E.D., Greenhow D.T. (1995) Hypoxia-selective agents derived from quinoxaline 1, 4-di-N-oxides. J Med Chem;38:1786-1792.
20. Monge A., Gil M.J., Gastelurrutia M.A., Pascual M. (1982) Sintesis y actividad bactericida de 1, 4-dioxidos de 2-acil o aroilquinoxalin etilenos y derivados pirazolicos. An Real Acad Farm;48:533-542.
21. Johnston J.D. (1968) U.S. Patent 3371090.
22. Haddadin M.J., Issidorides C.H. (1976) Application of benzofurazan oxide to synthesis of heteroaromatic N-oxides. Heterocycles;4:767-816.
23. Solano B., Junnotula V., Marin A., Villar R., Burguete A., Vicente E., Perez-Silanes S., Aldana I., Monge A., Dutta S., Sarkar U., Gates K.S. (2007) Synthesis and biological evaluation of new 2-arylcarbonyl-3-trifluoromethylquinoxaline 1, 4-di-N-oxide derivatives and their reduced analogues. J Med Chem;50:5485-5492.
24. Jaso A., Zarranz B., Aldana I., Monge A. (2003) Synthesis of new 2-acetyl and 2-benzoyl quinoxaline 1, 4-di-N-oxide derivatives as anti-Mycobacterium tuberculosis agents. Eur J Med Chem;38:791-800.
25. Reddy M.V., Billa V.K., Pallela V.R., Mallireddigari M.R., Boominathan R., Gabriel J.L., Reddy E.P. (2008) Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl) 3-trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitors. Bioorg Med Chem;16:3907-3916.
26. Re R., Pellegrini N., Proteggente A., Pannala A., Yang M., Rice-Evans C. (1999) Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic Biol Med;26:1231-1237.
27. Valko M., Leibfritz D., Moncol J., Cronin M.T.D., Mazur M., Telser J. (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol;39:44-84.
28. Ames B.N., Shigenaga M.K., Hagen T.M. (1993) Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA;90:7915-7922.
29. Pontiki E., Hadjipavlou-Litina D. (2006) Antioxidant and anti-inflammatory activity of aryl-acetic and hydroxamic acids as novel lipoxygenase inhibitors. Med Chem;2:251-264.
30. Halliwell B., Gutteridge J.M.C. (1984) Oxygen-toxicity, oxygen radicals, transition-metals and disease. Biochem J;219:1-14.
31. Liegeois C., Lermusieau G., Collin S. (2000) Measuring antioxidant efficiency of wort, malt, and hops against the 2, 2'-azobis(2-amidinopropane) dihydrochloride-induce oxidation of an aqueous dispersion of linoleic acid. J Agric Food Chem;48:1129-1134.
32. Taraporewala I.B., Kauffman J.M. (1990) Synthesis and structure-activity-relationships of anti-inflammatory 9, 10-dihydro-9-oxo-2-acridine-alkanoic acids and 4-(2-carboxyphenyl)aminobenzenealkanoic acids. J Pharm Sci;79:173-178.
33. Pontiki E., Hadjipavlou-Litina D. (2007) Synthesis and pharmacochemical evaluation of novel aryl-acetic acid inhibitors of lipoxygenase, antioxidants, and anti-inflammatory agents. Bioorg Med Chem;15:5819-5827.
34. Winter C.A., Garattini S., Dukes M.N.G. (1965) Non-Steroidal Anti-Inflammatory Drugs. Amsterdam: Excepta Medica.
35. Kuroda T., Suzuki F., Tamura T., Ohmori K., Hosoe H. (1992) A novel synthesis and potent antiinflammatory activity of 4-hydroxy-2(1h)-oxo-1-phenyl-1, 8-naphthyridine-3-carboxamides. J Med Chem;35:1130-1136.
36. Kim H.K., Miller L.F., Bambury R.E., Ritter H.W. (1977) Nitrones. 7. alpha.-Quinoxalinyl-N-substituted nitrone 1, 4-dioxides. J Med Chem;20:557-560.